Biomarkers Market Size, Share, and Trends 2024 to 2034

Biomarkers Market Size, Share By Type (Validation, Efficacy, and Safety), By Disease (Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, and Others),By Application (Personalized Medicines, Drug Discovery & Development, Diagnostics, and Others) - Global Industry Analysis, Trends, Growth, Segment Forecasts, Regional Outlook 2024 - 2033

  • Last Updated : June 2024
  • Report Code : 1182
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Biomarkers Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Biomarkers Market

5.1. Covid-19: Biomarkers Industry Impact
5.2. Biomarkers Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Biomarkers Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Biomarkers Market Players to deal with Covid-19 Pandemic Scenario

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Rising incidences of cancer
6.1.1.2. Increasing focus on establishment of biomarker-based diagnostic methods
6.1.2. Market Restraints
6.1.2.1. Stringent regulations
6.1.3. Market Opportunities
6.1.3.1. Rapidly expanding applications of biomarkers in diagnostics
6.1.3.2. Technological advancements

Chapter 7. Global Biomarkers Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Biomarkers Market Revenue by Market Players (2019 -2020)
7.1.1.2. Biomarkers Market Revenue Market Share by Market Players (2019 -2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Type Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Biomarkers Market, By Type

8.1. Biomarkers Market, by Type, 2019-2030
8.1.1. Validation
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Efficacy
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Safety
8.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Biomarkers Market, By Disease

9.1. Biomarkers Market, by Disease, 2019-2030
9.1.1. Neurological Diseases
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Cancer
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Immunological Diseases
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Cardiovascular Diseases
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Biomarkers Market, By Application

10.1. Biomarkers Market, by Application, 2019-2030
10.1.1. Personalized Medicines
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Drug Discovery & Development
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Diagnostics
10.1.3.1. Market Revenue and Forecast (2019-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Biomarkers Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Type(2019-2030)
11.1.2. Market Revenue Forecast by Disease (2019-2030)
11.1.3. Market Revenue Forecast by Application (2019-2030)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2019-2030)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2019-2030)
11.2. Europe
11.2.1. Market Revenue Forecast by Type (2019-2030)
11.2.2. Market Revenue Forecast by Disease (2019-2030)
11.2.3. Market Revenue Forecast by Application (2019-2030)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2019-2030)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2019-2030)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2019-2030)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2019-2030)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Type (2019-2030)
11.3.2. Market Revenue Forecast by Disease (2019-2030)
11.3.3. Market Revenue Forecast by Application (2019-2030)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2019-2030)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2019-2030)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2019-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2019-2030)
11.4. LATAM
11.4.1. Market Revenue Forecast by Type (2019-2030)
11.4.2. Market Revenue Forecast by Disease (2019-2030)
11.4.3. Market Revenue Forecast by Application (2019-2030)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2019-2030)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2019-2030)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Type (2019-2030)
11.5.2. Market Revenue Forecast by Disease (2019-2030)
11.5.3. Market Revenue Forecast by Application (2019-2030)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2019-2030)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2019-2030)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2019-2030)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2019-2030)

Chapter 12. Company Profiles

12.1. Bio-Rad Laboratories, Inc.
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Disease
12.1.3. Revenue, Price, and Gross Margin (2015-2020)
12.1.4. Recent Developments and Strategies
12.2. Qiagen
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Disease
12.2.3. Revenue, Price, and Gross Margin (2015-2020)
12.2.4. Recent Developments and Strategies
12.3. Epigenomics AG
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Disease
12.3.3. Revenue, Price, and Gross Margin (2015-2020)
12.3.4. Recent Developments and Strategies
12.4. Abbott
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Disease
12.4.3. Revenue, Price, and Gross Margin (2015-2020)
12.4.4. Recent Developments and Strategies
12.5. F. Hoffmann-La Roche Ltd.
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Disease
12.5.3. Revenue, Price, and Gross Margin (2015-2020)
12.5.4. Recent Developments and Strategies
12.6. Agilent Technologies, Inc.
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Disease
12.6.3. Revenue, Price, and Gross Margin (2015-2020)
12.6.4. Recent Developments and Strategies
12.7. Johnson & Johnson Services, Inc.
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Disease
12.7.3. Revenue, Price, and Gross Margin (2015-2020)
12.7.4. Recent Developments and Strategies
12.8. Abbott
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Disease
12.8.3. Revenue, Price, and Gross Margin (2015-2020)
12.8.4. Recent Developments and Strategies
12.9. Siemens
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Disease
12.9.3. Revenue, Price, and Gross Margin (2015-2020)
12.9.4. Recent Developments and Strategies
12.10. Thermo Fisher Scientific, Inc.
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Disease
12.10.3. Revenue, Price, and Gross Margin (2015-2020)
12.10.4. Recent Developments and Strategies

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client